+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030

  • PDF Icon

    Report

  • 540 Pages
  • September 2025
  • Region: Global
  • Markets and Markets
  • ID: 5311697
The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period. Molecular diagnostics plays a vital role in modern healthcare by enabling disease detection at the molecular and genetic level. These technologies offer high sensitivity and specificity, allowing for the early identification of pathogens and genetic abnormalities.

Continuous technological advancements, such as faster processing times, automated platforms, and improved assay designs, have significantly enhanced the reliability and accessibility of molecular tests. These innovations are significant in supporting large-scale testing efforts across diverse healthcare settings. Moreover, in countries like India, government and private sector initiatives contribute to increased public awareness and greater access to diagnostic and treatment services. Such efforts are expected to accelerate the adoption of molecular diagnostics in the coming years.

By sample type, the blood, serum, and plasma segment dominated the molecular diagnostics market in 2024.

By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market in 2024. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making fuel the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth.

By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to achieve the highest growth during the forecast period.

By technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & next-generation sequencing (NGS) segment is projected to witness the highest growth during the forecast period.

This surge is driven by their expanding use in detecting genetic mutations, identifying infectious agents, and guiding personalized treatment plans. The increasing turnaround time and data accuracy improvements have also broadened their adoption in research and clinical settings. Moreover, NGS is gaining traction due to its high-throughput capabilities and utility in comprehensive genomic profiling. As precision medicine continues to advance, the demand for sequencing-based diagnostics is set to rise significantly.

Asia Pacific is projected to be the fastest-growing regional market during the forecast period.

The market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to witness the highest growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region’s growth potential.

Break-up of primary participant profiles in the molecular diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, Director-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%
The key players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott Laboratories (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), test type (lab tests and PoC tests), sample type (blood, serum & plasma; urine; and other sample types), technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies), application {infectious disease diagnostics [hepatitis (hepatitis B, hepatitis C & other hepatitis diseases), sexually transmitted diseases (HIV, CT/NG, HPV, syphilis, & other sexually transmitted diseases), respiratory infectious diseases (tuberculosis, influenza, pharyngitis, & other respiratory infectious diseases), hospital-acquired infections, vector-borne diseases, and other infectious diseases], oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications}, technique (multiplex testing and singleplex testing), clinical application (diagnostic and screening), end user (hospitals & clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A thorough analysis of the key industry players provides insights into their business overview, solutions, key strategies, acquisitions, and agreements. This report also covers a competitive analysis of upcoming startups in the molecular diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report will help stakeholders understand the market pulse, providing information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers [Increasing prevalence of infectious diseases and cancer, growing R&D funding, surge in technological advancements in molecular diagnostics, and rising use of point-of-care (PoC) diagnostic tests], opportunities (Growing significance of companion diagnostics and increasing growth opportunities in emerging economies), restraints (Inadequate reimbursements and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape, operational barriers and labor shortage, and introduction of alternative technologies) influencing the growth of the molecular diagnostics market.
  • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market
  • Market Development: Comprehensive information about lucrative markets across varied regions
  • Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the molecular diagnostics market
  • Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US)

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation
1.3.2 Regional Scope
1.4 Inclusions & Exclusions
1.5 Years Considered
1.6 Currency Considered
1.7 Key Stakeholders
1.8 Summary of Changes
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Secondary Sources
2.1.1.2 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Primary Sources
2.1.2.2 Key Data from Primary Sources
2.1.2.3 Key Industry Insights
2.1.2.4 Breakdown of Primary Interviews
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.1.1 Approach 1: Company Revenue Estimation Approach
2.2.1.2 Approach 2: Presentation of Companies and Primary Interviews
2.2.1.3 Growth Forecast
2.2.1.4 Cagr Projections
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Assessment
2.5 Research Assumptions
2.5.1 Parametric Assumptions
2.6 Research Limitations
2.7 Risk Assessment
3 Executive Summary
4 Premium Insights
4.1 Molecular Diagnostics Market Overview
4.2 Molecular Diagnostics Market, by Product & Service, 2025 Vs. 2030
4.3 Molecular Diagnostics Market, by Test Type, 2025 Vs. 2030
4.4 Molecular Diagnostics Market, by Sample Type, 2025 Vs. 2030
4.5 Molecular Diagnostics Market, by Technology, 2025 Vs. 2030
4.6 Molecular Diagnostics Market, by Application, 2025 Vs. 2030
4.7 Molecular Diagnostics Market, by Technique, 2025 Vs. 2030
4.8 Molecular Diagnostics Market, by Clinical Application, 2025 Vs. 2030
4.9 Molecular Diagnostics Market, by End-user, 2025 Vs. 2030
4.10 Molecular Diagnostics Market: Geographic Growth Opportunities
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Infectious Diseases and Cancer
5.2.1.2 Growing R&D Funding
5.2.1.3 Surge in Technological Advancements
5.2.1.4 Rising Use of Point-Of-Care Diagnostic Tests
5.2.2 Restraints
5.2.2.1 Inadequate Reimbursements
5.2.2.2 High Cost of Molecular Diagnostic Instruments
5.2.3 Opportunities
5.2.3.1 Growing Significance of Companion Diagnostics
5.2.3.2 Increasing Growth Opportunities in Emerging Economies
5.2.4 Challenges
5.2.4.1 Changing Regulatory Landscape
5.2.4.2 Operational Barriers and Labor Shortage
5.2.4.3 Introduction of Alternative Technologies
5.3 Pricing Analysis
5.3.1 Average Selling Price Trend of Molecular Diagnostic Products
5.3.2 Average Selling Price Trend of Molecular Diagnostic Reagents & Kits, by Key Player
5.3.3 Average Selling Price Trend of Molecular Diagnostic Products, by Region
5.4 Patent Analysis
5.4.1 List of Major Patents
5.5 Value Chain Analysis
5.6 Supply Chain Analysis
5.7 Hs Codes
5.7.1 Import Scenario (Hs Code 3822)
5.7.2 Export Scenario (Hs Code 3822)
5.8 Ecosystem Analysis
5.9 Porter’S Five Forces Analysis
5.9.1 Threat from New Entrants
5.9.2 Threat from Substitutes
5.9.3 Bargaining Power of Buyers
5.9.4 Bargaining Power of Suppliers
5.9.5 Intensity of Competitive Rivalry
5.10 Regulatory Landscape
5.10.1 Regulatory Framework
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia-Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.5.1 Africa
5.10.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.11 Technology Analysis
5.11.1 Key Technologies
5.11.1.1 Polymerase Chain Reaction
5.11.2 Complementary Technologies
5.11.2.1 Microarrays
5.11.3 Adjacent Technologies
5.11.3.1 Next-Generation Sequencing
5.12 Key Conferences & Events, 2025-2026
5.13 Trends/Disruptions Impacting Customer Business
5.14 Key Stakeholders and Buying Criteria
5.14.1 Key Stakeholders in Buying Process
5.14.2 Buying Criteria
5.15 Investment and Funding Scenario
5.16 Case Study Analysis
5.16.1 Case Study 1: Using Molecular Diagnostics to Identify Atypical Respiratory Infection
5.16.2 Case Study 2: Implementing Rapid Pcr Testing to Improve Norovirus Diagnosis and Bed Management
5.16.3 Case Study 3: Rapid Pcr Testing Streamlined Emergency Care and Surgical Resource Management in German Hospital
5.17 Impact of AI/Generative AI on Molecular Diagnostics Market
5.17.1 Introduction
5.17.2 Market Potential of AI
5.17.2.1 Key Use Cases
5.17.3 Implementation of AI by Key Companies
5.17.4 Future of AI in Molecular Diagnostics Market
5.18 US 2025 Tariff
5.18.1 Introduction
5.18.2 Key Tariff Rates
5.18.3 Price Impact Analysis
5.18.4 Impact on Region
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia-Pacific
5.18.5 Impact on End-Use Industries
5.18.5.1 Hospitals & Clinics
5.18.5.2 Diagnostic Laboratories
6 Molecular Diagnostics Market, by Product & Service
6.1 Introduction
6.2 Reagents & Kits
6.2.1 Increasing Awareness About Early Disease Detection to Propel Market
6.3 Instruments
6.3.1 Rising Need for Quick and Accurate Test Results to Boost Market
6.4 Services & Software
6.4.1 Growing Uptake of Advanced Instruments to Drive Market
7 Molecular Diagnostics Market, by Test Type
7.1 Introduction
7.2 Lab Tests
7.2.1 Increasing Need for Automation and Efficient Disease Testing to Drive Market
7.3 Poc Tests
7.3.1 Increased Investment by Public Health Agencies and Governments to Boost Market
8 Molecular Diagnostics Market, by Sample Type
8.1 Introduction
8.2 Blood, Serum, and Plasma
8.2.1 Increasing Utilization in Genetic Testing, Infectious Disease Diagnosis, and Cancer Diagnostics to Propel Market
8.3 Urine
8.3.1 Need for Non-Invasive and Easy Sample Collection Technique to Fuel Market
8.4 Other Sample Types
9 Molecular Diagnostics Market, by Technology
9.1 Introduction
9.2 Polymerase Chain Reaction
9.2.1 Rising Use in Proteomics and Genomics to Aid Growth
9.3 Isothermal Nucleic Acid Amplification Technology
9.3.1 Need for Prompt Diagnosis to Stimulate Growth
9.4 Dna Sequencing & Next-Generation Sequencing
9.4.1 Growing Technological Advancements to Drive Market
9.5 In Situ Hybridization
9.5.1 Rising Applications in Diagnosing Chromosomal Abnormalities and Gene Mapping to Boost Market
9.6 Dna Microarrays
9.6.1 Surge in Advancements in Design, Density, and Detection Techniques to Fuel Market
9.7 Other Technologies
10 Molecular Diagnostics Market, by Application
10.1 Introduction
10.2 Infectious Disease Diagnostics
10.2.1 Sexually Transmitted Diseases
10.2.1.1 Ct/Ng
10.2.1.1.1 Growing Development of Novel Assays to Boost Market
10.2.1.2 Hiv
10.2.1.2.1 Increasing Blood Transfusions and Blood Donations to Propel Market
10.2.1.3 Hpv
10.2.1.3.1 Rising Cases of Cervical Cancer to Augment Growth
10.2.1.4 Syphilis
10.2.1.4.1 Growing Demand for Affordable and Rapid Molecular Diagnostic Solutions to Drive Market
10.2.1.5 Other Sexually Transmitted Diseases
10.2.2 Hepatitis
10.2.2.1 Hepatitis B
10.2.2.1.1 Need for Ongoing Management and Monitoring of Virus to Drive Market
10.2.2.2 Hepatitis C
10.2.2.2.1 Favorable Government Initiatives to Support Growth
10.2.2.3 Other Hepatitis Diseases
10.2.3 Respiratory Infectious Diseases
10.2.3.1 Tuberculosis
10.2.3.1.1 Rising Focus on Reducing Tuberculosis Deaths to Fuel Market
10.2.3.2 Influenza
10.2.3.2.1 Growing Strains and Subtypes to Drive Market
10.2.3.3 Pharyngitis
10.2.3.3.1 Need to Differentiate Between Bacterial and Viral Infections to Fuel Growth
10.2.3.4 Other Respiratory Infectious Diseases
10.2.4 Hospital-Acquired Infections
10.2.4.1 Booming Geriatric Population to Aid Growth
10.2.5 Vector-Borne Diseases
10.2.5.1 Growing Focus on Disease Surveillance to Propel Market
10.2.6 Other Infectious Diseases
10.3 Oncology Testing
10.3.1 Breast Cancer
10.3.1.1 Increasing Need to Improve Survival Rates to Support Growth
10.3.2 Colorectal Cancer
10.3.2.1 Rising Demand for Biomarkers to Fuel Market
10.3.3 Lung Cancer
10.3.3.1 Increasing Use of Predictive Biomarkers to Drive Market
10.3.4 Prostate Cancer
10.3.4.1 Surge in Advancements in Genomic Technologies to Aid Growth
10.3.5 Other Cancer Types
10.4 Genetic Testing
10.4.1 Growing Importance of Diagnosing and Managing Rare Genetic Diseases to Propel Market
10.5 Other Applications
11 Molecular Diagnostics Market, by Technique
11.1 Introduction
11.2 Multiplex Testing
11.2.1 Rising Demand for Quick Diagnosis to Promote Growth
11.3 Singleplex Testing
11.3.1 Need for Affordable Testing to Augment Growth
12 Molecular Diagnostics Market, by Clinical Application
12.1 Introduction
12.2 Diagnostic
12.2.1 Increasing Clinical Need for Confirmatory Testing and Timely Treatment to Drive Market
12.3 Screening
12.3.1 Growing Importance of Early Infectious Disease Screening to Propel Market Expansion
13 Molecular Diagnostics Market, by End-user
13.1 Introduction
13.2 Diagnostic Laboratories
13.2.1 Increased Outsourcing of Laboratory Diagnoses for Cost Reduction to Aid Growth
13.3 Hospitals & Clinics
13.3.1 Growing Focus on Healthcare Systems to Stimulate Growth
13.4 Other End-users
14 Molecular Diagnostics Market, by Region
14.1 Introduction
14.2 North America
14.2.1 Macroeconomic Outlook
14.2.2 US
14.2.2.1 Presence of Advanced Healthcare Infrastructure and High Healthcare Expenditures to Drive Market
14.2.3 Canada
14.2.3.1 Growing Focus on Genomic Research to Fuel Market
14.3 Europe
14.3.1 Macroeconomic Outlook
14.3.2 Germany
14.3.2.1 Robust Healthcare Spending and Increasing Per Capita Disposable Income to Propel Market
14.3.3 UK
14.3.3.1 Expanding Community-Based Diagnostics to Drive Adoption of Molecular Diagnostics
14.3.4 France
14.3.4.1 Rising R&D Expenditure for Product Launches and Development of New Technologies to Augment Growth
14.3.5 Italy
14.3.5.1 Growing Demographic Shift Toward Elderly Population to Support Market
14.3.6 Spain
14.3.6.1 Surge in Demand for Genetic and Prenatal Testing to Aid Growth
14.3.7 Russia
14.3.7.1 Increasing Access to Quality Healthcare to Boost Market Growth
14.3.8 Switzerland
14.3.8.1 Rising Healthcare Spending for New Medications and Therapies to Drive Market
14.3.9 Rest of Europe
14.4 Asia-Pacific
14.4.1 Macroeconomic Outlook
14.4.2 China
14.4.2.1 Growing Public Access to Modern Healthcare to Drive Market
14.4.3 Japan
14.4.3.1 Universal Healthcare Reimbursement Policy to Support Market
14.4.4 India
14.4.4.1 Increasing Penetration of Medical Insurance, Hospital Setups, and Foreign Direct Investments to Fuel Market
14.4.5 Australia
14.4.5.1 Rising Technological Advancements to Stimulate Growth
14.4.6 South Korea
14.4.6.1 Favorable Government Initiatives for Promoting Medical Tourism to Support Growth
14.4.7 Rest of Asia-Pacific
14.5 Latin America
14.5.1 Macroeconomic Outlook
14.5.2 Brazil
14.5.2.1 Universal Healthcare Access to Drive Adoption in Brazil
14.5.3 Mexico
14.5.3.1 Booming Medical Tourism Industry to Aid Growth
14.5.4 Rest of Latin America
14.6 Middle East & Africa
14.6.1 Macroeconomic Outlook
14.6.2 Saudi Arabia
14.6.2.1 Rising Government Healthcare Expenditure to Boost Market
14.6.3 Uae
14.6.3.1 Improvements in Healthcare Infrastructure to Support Growth
14.6.4 Rest of Middle East & Africa
15 Competitive Landscape
15.1 Introduction
15.2 Key Player Strategies/Right to Win
15.2.1 Overview of Strategies Adopted by Key Players in Molecular Diagnostics Market
15.3 Revenue Share Analysis
15.4 Market Share Analysis, 2024
15.5 Company Evaluation Matrix: Key Players, 2024
15.5.1 Stars
15.5.2 Emerging Leaders
15.5.3 Pervasive Players
15.5.4 Participants
15.5.5 Company Footprint: Key Players, 2024
15.5.5.1 Company Footprint
15.5.5.2 Region Footprint
15.5.5.3 Product & Service Footprint
15.5.5.4 Sample Type Footprint
15.5.5.5 Application Footprint
15.6 Company Evaluation Matrix: Startups/Smes, 2024
15.6.1 Progressive Companies
15.6.2 Responsive Companies
15.6.3 Dynamic Companies
15.6.4 Starting Blocks
15.6.5 Competitive Benchmarking: Startups/Smes, 2024
15.6.5.1 Detailed List of Key Startups/Smes
15.6.5.2 Competitive Benchmarking of Startups/Smes
15.7 Company Valuation & Financial Metrics
15.7.1 Financial Metrics
15.7.2 Company Valuation
15.8 Brand/Product Comparison
15.9 Competitive Scenario
15.9.1 Product/Services Launches and Approvals
15.9.2 Deals
15.9.3 Expansions
16 Company Profiles
16.1 Key Players
16.1.1 Danaher Corporation
16.1.1.1 Business Overview
16.1.1.2 Products/Services Offered
16.1.1.3 Recent Developments
16.1.1.3.1 Product/Service Launches and Approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 Publisher View
16.1.1.4.1 Right to Win
16.1.1.4.2 Strategic Choices
16.1.1.4.3 Weaknesses and Competitive Threats
16.1.2 F. Hoffmann-La Roche Ltd
16.1.2.1 Business Overview
16.1.2.2 Products/Services Offered
16.1.2.3 Recent Developments
16.1.2.3.1 Product/Service Launches and Approvals
16.1.2.3.2 Deals
16.1.2.4 Publisher View
16.1.2.4.1 Right to Win
16.1.2.4.2 Strategic Choices
16.1.2.4.3 Weaknesses and Competitive Threats
16.1.3 Illumina, Inc.
16.1.3.1 Business Overview
16.1.3.2 Products/Services Offered
16.1.3.3 Recent Developments
16.1.3.3.1 Product/Service Launches and Approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 Publisher View
16.1.3.4.1 Right to Win
16.1.3.4.2 Strategic Choices
16.1.3.4.3 Weaknesses and Competitive Threats
16.1.4 Hologic, Inc.
16.1.4.1 Business Overview
16.1.4.2 Products/Services Offered
16.1.4.3 Recent Developments
16.1.4.3.1 Product/Service Launches and Approvals
16.1.4.3.2 Deals
16.1.4.4 Publisher View
16.1.4.4.1 Right to Win
16.1.4.4.2 Strategic Choices
16.1.4.4.3 Weaknesses and Competitive Threats
16.1.5 Biomérieux
16.1.5.1 Business Overview
16.1.5.2 Products/Services Offered
16.1.5.3 Recent Developments
16.1.5.3.1 Product/Service Launches and Approvals
16.1.5.3.2 Deals
16.1.5.4 Publisher View
16.1.5.4.1 Right to Win
16.1.5.4.2 Strategic Choices
16.1.5.4.3 Weaknesses and Competitive Threats
16.1.6 Abbott Laboratories
16.1.6.1 Business Overview
16.1.6.2 Products/Services Offered
16.1.6.3 Recent Developments
16.1.6.3.1 Product/Service Launches and Approvals
16.1.6.3.2 Deals
16.1.7 Thermo Fisher Scientific Inc.
16.1.7.1 Business Overview
16.1.7.2 Products/Services Offered
16.1.7.3 Recent Developments
16.1.7.3.1 Product/Service Launches and Approvals
16.1.7.3.2 Deals
16.1.8 Qiagen N.V.
16.1.8.1 Business Overview
16.1.8.2 Products/Services Offered
16.1.8.3 Recent Developments
16.1.8.3.1 Product/Service Launches and Approvals
16.1.8.3.2 Deals
16.1.8.3.3 Expansions
16.1.9 Revvity, Inc.
16.1.9.1 Business Overview
16.1.9.2 Products/Services Offered
16.1.10 Myriad Genetics, Inc.
16.1.10.1 Business Overview
16.1.10.2 Products/Services Offered
16.1.10.3 Recent Developments
16.1.10.3.1 Product/Service Launches and Approvals
16.1.10.3.2 Deals
16.1.11 Siemens Healthineers Ag
16.1.11.1 Business Overview
16.1.11.2 Products/Services Offered
16.1.11.3 Recent Developments
16.1.11.3.1 Product/Service Launches and Approvals
16.1.11.3.2 Deals
16.1.11.3.3 Expansions
16.2 Other Players
16.2.1 Becton, Dickinson and Company (Bd)
16.2.2 Grifols, S.A.
16.2.3 Quidelortho Corporation
16.2.4 Diasorin S.P.A.
16.2.5 Exact Sciences Corporation
16.2.6 Genetic Signatures
16.2.7 Agilent Technologies, Inc.
16.2.8 Mdxhealth
16.2.9 Biocartis
16.2.10 Medigen Biotechnology Corp.
16.2.11 Vela Diagnostics
16.2.12 Amoy Diagnostics Co. Ltd.
16.2.13 Bruker Corporation (Elitechgroup)
16.2.14 Molbio Diagnostics Limited
16.2.15 Geneombiotechnologies
16.2.16 Savyon Diagnostics
16.2.17 Uniogen Oy
17 Appendix
17.1 Discussion Guide
17.2 Knowledgestore: Subscription Portal
17.3 Customization Options
17.4 Related Reports
17.5 Author Details
List of Tables
Table 1 Molecular Diagnostics Market: Key Data from Primary Sources
Table 2 Molecular Diagnostics Market: Risk Assessment Analysis
Table 3 Types of Cancer Cases Worldwide, 2022 Vs. 2045
Table 4 Number of Cancer Patients Worldwide, by Region, 2022 Vs. 2035 Vs. 2045
Table 5 Average Selling Price Trend of Molecular Diagnostic Products, 2023-2025 (USD)
Table 6 Average Selling Price Trend of Molecular Diagnostic Reagents & Kits, by Key Player, 2023-2025 (USD)
Table 7 Average Selling Price Trend of Molecular Diagnostic Products, By Region, 2023-2025 (USD)
Table 8 List of Major Patents, 2022-2024
Table 9 Import Data for Hs Code 3822-Compliant Products, by Country, 2020-2024 (USD Million)
Table 10 Export Data for Hs Code 3822-Compliant Products, by Country, 2020-2024 (USD Million)
Table 11 Molecular Diagnostics Market: Role of Companies in Ecosystem
Table 12 Impact of Porter’S Forces on Molecular Diagnostics Market
Table 13 Classification of Ivd Devices in Europe
Table 14 Time, Cost, and Complexity of Device Registration Process in Japan
Table 15 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 16 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 17 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 18 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 19 Rest of the World: Regulatory Bodies, Government Agencies, and Other Organizations
Table 20 Molecular Diagnostics Market: Key Conferences & Events, 2025-2026
Table 21 Influence of Stakeholders on Buying Process, By Product & Service (%)
Table 22 Key Buying Criteria, by Product & Service
Table 23 Reciprocal Tariff Rates Adjusted by US
Table 24 Molecular Diagnostics Market, by Product & Service, 2023-2030 (USD Million)
Table 25 Key Reagents and Kits Available in Market
Table 26 Molecular Diagnostics Market for Reagents & Kits, by Region, 2023-2030 (USD Million)
Table 27 North America: Molecular Diagnostics Market for Reagents & Kits, By Country, 2023-2030 (USD Million)
Table 28 Europe: Molecular Diagnostics Market for Reagents & Kits, By Country/Region, 2023-2030 (USD Million)
Table 29 Asia-Pacific: Molecular Diagnostics Market for Reagents & Kits, By Country/Region, 2023-2030 (USD Million)
Table 30 Latin America: Molecular Diagnostics Market for Reagents & Kits, By Country/Region, 2023-2030 (USD Million)
Table 31 Middle East & Africa: Molecular Diagnostics Market for Reagents & Kits, by Country/Region, 2023-2030 (USD Million)
Table 32 Key Instruments Available in Market
Table 33 Molecular Diagnostics Market for Instruments, by Region, 2023-2030 (USD Million)
Table 34 North America: Molecular Diagnostics Market for Instruments, By Country, 2023-2030 (USD Million)
Table 35 Europe: Molecular Diagnostics Market for Instruments, By Country/Region, 2023-2030 (USD Million)
Table 36 Asia-Pacific: Molecular Diagnostics Market for Instruments, By Country/Region, 2023-2030 (USD Million)
Table 37 Latin America: Molecular Diagnostics Market for Instruments, By Country/Region, 2023-2030 (USD Million)
Table 38 Middle East & Africa: Molecular Diagnostics Market for Instruments, by Country/Region, 2023-2030 (USD Million)
Table 39 Key Software Solutions Available Worldwide
Table 40 Molecular Diagnostics Market for Services & Software, by Region, 2023-2030 (USD Million)
Table 41 North America: Molecular Diagnostics Market for Services & Software, by Country, 2023-2030 (USD Million)
Table 42 Europe: Molecular Diagnostics Market for Services & Software, By Country/Region, 2023-2030 (USD Million)
Table 43 Asia-Pacific: Molecular Diagnostics Market for Services & Software, by Country/Region, 2023-2030 (USD Million)
Table 44 Latin America: Molecular Diagnostics Market for Services & Software, by Country/Region, 2023-2030 (USD Million)
Table 45 Middle East & Africa: Molecular Diagnostics Market for Services & Software, by Country/Region, 2023-2030 (USD Million)
Table 46 Molecular Diagnostics Market, by Test Type, 2023-2030 (USD Million)
Table 47 Key Laboratory Testing Instruments Available in Market
Table 48 Molecular Diagnostics Market for Lab Tests, by Region, 2023-2030 (USD Million)
Table 49 North America: Molecular Diagnostics Market for Lab Tests, By Country, 2023-2030 (USD Million)
Table 50 Europe: Molecular Diagnostics Market for Lab Tests, by Country/Region, 2023-2030 (USD Million)
Table 51 Asia-Pacific: Molecular Diagnostics Market for Lab Tests, By Country/Region, 2023-2030 (USD Million)
Table 52 Latin America: Molecular Diagnostics Market for Lab Tests, By Country/Region, 2023-2030 (USD Million)
Table 53 Middle East & Africa: Molecular Diagnostics Market for Lab Tests, By Country/Region, 2023-2030 (USD Million)
Table 54 Key Poc Testing Products Available in Market
Table 55 Molecular Diagnostics Market for Poc Tests, by Region, 2023-2030 (USD Million)
Table 56 North America: Molecular Diagnostics Market for Poc Tests, By Country, 2023-2030 (USD Million)
Table 57 Europe: Molecular Diagnostics Market for Poc Tests, By Country/Region, 2023-2030 (USD Million)
Table 58 Asia-Pacific: Molecular Diagnostics Market for Poc Tests, By Country/Region, 2023-2030 (USD Million)
Table 59 Latin America: Molecular Diagnostics Market for Poc Tests, By Country/Region, 2023-2030 (USD Million)
Table 60 Middle East & Africa: Molecular Diagnostics Market for Poc Tests, By Country/Region, 2023-2030 (USD Million)
Table 61 Molecular Diagnostics Market, by Sample Type, 2023-2030 (USD Million)
Table 62 Key Blood, Serum, and Plasma Sample Type-Based Products Available in Market
Table 63 Molecular Diagnostics Market for Blood, Serum, and Plasma, By Region, 2023-2030 (USD Million)
Table 64 North America: Molecular Diagnostics Market for Blood, Serum, and Plasma, by Country, 2023-2030 (USD Million)
Table 65 Europe: Molecular Diagnostics Market for Blood, Serum, and Plasma Samples, by Country/Region, 2023-2030 (USD Million)
Table 66 Asia-Pacific: Molecular Diagnostics Market for Blood, Serum, and Plasma, by Country/Region, 2023-2030 (USD Million)
Table 67 Latin America: Molecular Diagnostics Market for Blood, Serum, and Plasma, by Country/Region, 2023-2030 (USD Million)
Table 68 Middle East & Africa: Molecular Diagnostics Market for Blood, Serum, and Plasma, by Country/Region, 2023-2030 (USD Million)
Table 69 Key Urine Sample Type-Based Products Available in Market
Table 70 Molecular Diagnostics Market for Urine, by Region, 2023-2030 (USD Million)
Table 71 North America: Molecular Diagnostics Market for Urine, by Country, 2023-2030 (USD Million)
Table 72 Europe: Molecular Diagnostics Market for Urine, by Country/Region, 2023-2030 (USD Million)
Table 73 Asia-Pacific: Molecular Diagnostics Market for Urine, By Country/Region, 2023-2030 (USD Million)
Table 74 Latin America: Molecular Diagnostics Market for Urine, By Country/Region, 2023-2030 (USD Million)
Table 75 Middle East & Africa: Molecular Diagnostics Market for Urine, By Country/Region, 2023-2030 (USD Million)
Table 76 Other Sample Type-Based Products Available in Market
Table 77 Molecular Diagnostics Market for Other Sample Types, by Region, 2023-2030 (USD Million)
Table 78 North America: Molecular Diagnostics Market for Other Sample Types, by Country, 2023-2030 (USD Million)
Table 79 Europe: Molecular Diagnostics Market for Other Sample Types, By Country/Region, 2023-2030 (USD Million)
Table 80 Asia-Pacific: Molecular Diagnostics Market for Other Sample Types, By Country/Region, 2023-2030 (USD Million)
Table 81 Latin America: Molecular Diagnostics Market for Other Sample Types, by Country/Region, 2023-2030 (USD Million)
Table 82 Middle East & Africa: Molecular Diagnostics Market for Other Sample Types, by Country/Region, 2023-2030 (USD Million)
Table 83 Molecular Diagnostics Market, by Technology, 2023-2030 (USD Million)
Table 84 Key Polymerase Chain Reaction Instruments Available in Market
Table 85 Molecular Diagnostics Market for Polymerase Chain Reaction, By Region, 2023-2030 (USD Million)
Table 86 Molecular Diagnostics Market for Polymerase Chain Reaction, By Product & Service, 2023-2030 (USD Million)
Table 87 North America: Molecular Diagnostics Market for Polymerase Chain Reaction, by Country/Region, 2023-2030 (USD Million)
Table 88 Europe: Molecular Diagnostics Market for Polymerase Chain Reaction, by Country/Region, 2023-2030 (USD Million)
Table 89 Asia-Pacific: Molecular Diagnostics Market for Polymerase Chain Reaction, by Country/Region, 2023-2030 (USD Million)
Table 90 Latin America: Molecular Diagnostics Market for Polymerase Chain Reaction, by Country/Region, 2023-2030 (USD Million)
Table 91 Middle East & Africa: Molecular Diagnostics Market for Polymerase Chain Reaction, by Country/Region, 2023-2030 (USD Million)
Table 92 Key Isothermal Nucleic Acid Amplification Technology Instruments Available in Market
Table 93 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Region, 2023-2030 (USD Million)
Table 94 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Product & Service, 2023-2030 (USD Million)
Table 95 North America: Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Country, 2023-2030 (USD Million)
Table 96 Europe: Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Country/Region, 2023-2030 (USD Million)
Table 97 Asia-Pacific: Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Country/Region, 2023-2030 (USD Million)
Table 98 Latin America: Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Country/Region, 2023-2030 (USD Million)
Table 99 Middle East & Africa: Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, by Country/Region, 2023-2030 (USD Million)
Table 100 Key Next-Generation Sequencing-Based Instruments Available in Market
Table 101 Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Region, 2023-2030 (USD Million)
Table 102 Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Product & Service, 2023-2030 (USD Million)
Table 103 North America: Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Country, 2023-2030 (USD Million)
Table 104 Europe: Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Country/Region, 2023-2030 (USD Million)
Table 105 Asia-Pacific: Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Country/Region, 2023-2030 (USD Million)
Table 106 Latin America: Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Country/Region, 2023-2030 (USD Million)
Table 107 Middle East & Africa: Molecular Diagnostics Market for Dna Sequencing & Next-Generation Sequencing, by Country/Region, 2023-2030 (USD Million)
Table 108 Key in Situ Hybridization Products Available in Market
Table 109 Molecular Diagnostics Market for in Situ Hybridization, by Region, 2023-2030 (USD Million)
Table 110 Molecular Diagnostics Market for in Situ Hybridization, by Product & Service, 2023-2030 (USD Million)
Table 111 North America: Molecular Diagnostics Market for in Situ Hybridization, by Country, 2023-2030 (USD Million)
Table 112 Europe: Molecular Diagnostics Market for in Situ Hybridization, By Country/Region, 2023-2030 (USD Million)
Table 113 Asia-Pacific: Molecular Diagnostics Market for in Situ Hybridization, by Country/Region, 2023-2030 (USD Million)
Table 114 Latin America: Molecular Diagnostics Market for in Situ Hybridization, by Country/Region, 2023-2030 (USD Million)
Table 115 Middle East & Africa: Molecular Diagnostics Market for in Situ Hybridization, by Country/Region, 2023-2030 (USD Million)
Table 116 Key Microarray-Based Products Available in Market
Table 117 Molecular Diagnostics Market for Dna Microarrays, by Region, 2023-2030 (USD Million)
Table 118 Molecular Diagnostics Market for Dna Microarrays, by Product & Service, 2023-2030 (USD Million)
Table 119 North America: Molecular Diagnostics Market for Dna Microarrays, by Country, 2023-2030 (USD Million)
Table 120 Europe: Molecular Diagnostics Market for Dna Microarrays, By Country/Region, 2023-2030 (USD Million)
Table 121 Asia-Pacific: Molecular Diagnostics Market for Dna Microarrays, By Country/Region, 2023-2030 (USD Million)
Table 122 Latin America: Molecular Diagnostics Market for Dna Microarrays, By Country/Region, 2023-2030 (USD Million)
Table 123 Middle East & Africa: Molecular Diagnostics Market for Dna Microarrays, by Country/Region, 2023-2030 (USD Million)
Table 124 Molecular Diagnostics Market for Other Technologies, by Region, 2023-2030 (USD Million)
Table 125 Molecular Diagnostics Market for Other Technologies, by Product & Service, 2023-2030 (USD Million)
Table 126 North America: Molecular Diagnostics Market for Other Technologies, by Country, 2023-2030 (USD Million)
Table 127 Europe: Molecular Diagnostics Market for Other Technologies, By Country/Region, 2023-2030 (USD Million)
Table 128 Asia-Pacific: Molecular Diagnostics Market for Other Technologies, by Country/Region, 2023-2030 (USD Million)
Table 129 Latin America: Molecular Diagnostics Market for Other Technologies, by Country/Region, 2023-2030 (USD Million)
Table 130 Middle East & Africa: Molecular Diagnostics Market for Other Technologies, by Country/Region, 2023-2030 (USD Million)
Table 131 Molecular Diagnostics Market, by Application, 2023-2030 (USD Million)
Table 132 Key Infectious Disease Diagnostic Products Available in Market
Table 133 Molecular Diagnostics Market for Infectious Disease Diagnostics, By Region, 2023-2030 (USD Million)
Table 134 Molecular Diagnostics Market for Infectious Disease Diagnostics, By Type, 2023-2030 (USD Million)
Table 135 North America: Molecular Diagnostics Market for Infectious Disease Diagnostics, by Country, 2023-2030 (USD Million)
Table 136 Europe: Molecular Diagnostics Market for Infectious Disease Diagnostics, by Country/Region, 2023-2030 (USD Million)
Table 137 Asia-Pacific: Molecular Diagnostics Market for Infectious Disease Diagnostics, by Country/Region, 2023-2030 (USD Million)
Table 138 Latin America: Molecular Diagnostics Market for Infectious Disease Diagnostics, by Country/Region, 2023-2030 (USD Million)
Table 139 Middle East & Africa: Molecular Diagnostics Market for Infectious Disease Diagnostics, by Country/Region, 2023-2030 (USD Million)
Table 140 Molecular Diagnostics Market for Sexually Transmitted Diseases, By Region, 2023-2030 (USD Million)
Table 141 Molecular Diagnostics Market for Sexually Transmitted Diseases, By Type, 2023-2030 (USD Million)
Table 142 North America: Molecular Diagnostics Market for Sexually Transmitted Diseases, by Country, 2023-2030 (USD Million)
Table 143 Europe: Molecular Diagnostics Market for Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 144 Asia-Pacific: Molecular Diagnostics Market for Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 145 Latin America: Molecular Diagnostics Market for Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 146 Middle East & Africa: Molecular Diagnostics Market for Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 147 Key Ct/Ng Molecular Diagnostic Products Available in Market
Table 148 Molecular Diagnostics Market for Ct/Ng, by Region, 2023-2030 (USD Million)
Table 149 North America: Molecular Diagnostics Market for Ct/Ng, by Country, 2023-2030 (USD Million)
Table 150 Europe: Molecular Diagnostics Market for Ct/Ng, by Country/Region, 2023-2030 (USD Million)
Table 151 Asia-Pacific: Molecular Diagnostics Market Ct/Ng, by Country/Region, 2023-2030 (USD Million)
Table 152 Latin America: Molecular Diagnostics Market for Ct/Ng, By Country/Region, 2023-2030 (USD Million)
Table 153 Middle East & Africa: Molecular Diagnostics Market for Ct/Ng, By Country/Region, 2023-2030 (USD Million)
Table 154 Key Hiv Molecular Diagnostic Products Available in Market
Table 155 Molecular Diagnostics Market for Hiv, by Region, 2023-2030 (USD Million)
Table 156 North America: Molecular Diagnostics Market for Hiv, by Country, 2023-2030 (USD Million)
Table 157 Europe: Molecular Diagnostics Market for Hiv, by Country/Region, 2023-2030 (USD Million)
Table 158 Asia-Pacific: Molecular Diagnostics Market Hiv, by Country/Region, 2023-2030 (USD Million)
Table 159 Latin America: Molecular Diagnostics Market for Hiv, By Country/Region, 2023-2030 (USD Million)
Table 160 Middle East & Africa: Molecular Diagnostics Market for Hiv, By Country/Region, 2023-2030 (USD Million)
Table 161 Key Hpv Molecular Diagnostic Products Available in Market
Table 162 Molecular Diagnostics Market for Hpv, by Region, 2023-2030 (USD Million)
Table 163 North America: Molecular Diagnostics Market for Hpv, by Country, 2023-2030 (USD Million)
Table 164 Europe: Molecular Diagnostics Market for Hpv, by Country/Region, 2023-2030 (USD Million)
Table 165 Asia-Pacific: Molecular Diagnostics Market Hpv, by Country/Region, 2023-2030 (USD Million)
Table 166 Latin America: Molecular Diagnostics Market for Hpv, By Country/Region, 2023-2030 (USD Million)
Table 167 Middle East & Africa: Molecular Diagnostics Market for Hpv, by Country/Region, 2023-2030 (USD Million)
Table 168 Key Syphilis Molecular Diagnostic Products Available in Market
Table 169 Molecular Diagnostics Market for Syphilis, by Region, 2023-2030 (USD Million)
Table 170 North America: Molecular Diagnostics Market for Syphilis, By Country, 2023-2030 (USD Million)
Table 171 Europe: Molecular Diagnostics Market for Syphilis, By Country/Region, 2023-2030 (USD Million)
Table 172 Asia-Pacific: Molecular Diagnostics Market for Syphilis, By Country/Region, 2023-2030 (USD Million)
Table 173 Latin America: Molecular Diagnostics Market for Syphilis, By Country/Region, 2023-2030 (USD Million)
Table 174 Middle East & Africa: Molecular Diagnostics Market for Syphilis, By Country/Region, 2023-2030 (USD Million)
Table 175 Other Sexually Transmitted Disease Molecular Diagnostic Products Available in Market
Table 176 Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Region, 2023-2030 (USD Million)
Table 177 North America: Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Country, 2023-2030 (USD Million)
Table 178 Europe: Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 179 Asia-Pacific: Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 180 Latin America: Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 181 Middle East & Africa: Molecular Diagnostics Market for Other Sexually Transmitted Diseases, by Country/Region, 2023-2030 (USD Million)
Table 182 Key Hepatitis Molecular Diagnostic Products Available in Market
Table 183 Molecular Diagnostics Market for Hepatitis, by Region, 2023-2030 (USD Million)
Table 184 Molecular Diagnostics Market for Hepatitis, by Type, 2023-2030 (USD Million)
Table 185 North America: Molecular Diagnostics Market for Hepatitis, By Country, 2023-2030 (USD Million)
Table 186 Europe: Molecular Diagnostics Market for Hepatitis, By Country/Region, 2023-2030 (USD Million)
Table 187 Asia-Pacific: Molecular Diagnostics Market for Hepatitis, By Country/Region, 2023-2030 (USD Million)
Table 188 Latin America: Molecular Diagnostics Market for Hepatitis, By Country/Region, 2023-2030 (USD Million)
Table 189 Middle East & Africa: Molecular Diagnostics Market for Hepatitis, By Country/Region, 2023-2030 (USD Million)
Table 190 Molecular Diagnostics Market for Hepatitis B, by Region, 2023-2030 (USD Million)
Table 191 North America: Molecular Diagnostics Market for Hepatitis B, By Country, 2023-2030 (USD Million)
Table 192 Europe: Molecular Diagnostics Market for Hepatitis B, By Country/Region, 2023-2030 (USD Million)
Table 193 Asia-Pacific: Molecular Diagnostics Market for Hepatitis B, By Country/Region, 2023-2030 (USD Million)
Table 194 Latin America: Molecular Diagnostics Market for Hepatitis B, By Country/Region, 2023-2030 (USD Million)
Table 195 Middle East & Africa: Molecular Diagnostics Market for Hepatitis B, By Country/Region, 2023-2030 (USD Million)
Table 196 Molecular Diagnostics Market for Hepatitis C, by Region, 2023-2030 (USD Million)
Table 197 North America: Molecular Diagnostics Market for Hepatitis C, By Country, 2023-2030 (USD Million)
Table 198 Europe: Molecular Diagnostics Market for Hepatitis C, By Country/Region, 2023-2030 (USD Million)
Table 199 Asia-Pacific: Molecular Diagnostics Market for Hepatitis C, By Country/Region, 2023-2030 (USD Million)
Table 200 Latin America: Molecular Diagnostics Market for Hepatitis C, by Country/Region, 2023-2030 (USD Million)
Table 201 Middle East & Africa: Molecular Diagnostics Market for Hepatitis C, By Country/Region, 2023-2030 (USD Million)
Table 202 Molecular Diagnostics Market for Other Hepatitis Diseases, by Region, 2023-2030 (USD Million)
Table 203 North America: Molecular Diagnostics Market for Other Hepatitis Diseases, by Country, 2023-2030 (USD Million)
Table 204 Europe: Molecular Diagnostics Market for Other Hepatitis Diseases, by Country/Region, 2023-2030 (USD Million)
Table 205 Asia-Pacific: Molecular Diagnostics Market for Other Hepatitis Diseases, by Country/Region, 2023-2030 (USD Million)
Table 206 Latin America: Molecular Diagnostics Market for Other Hepatitis Diseases, by Country/Region, 2023-2030 (USD Million)
Table 207 Middle East & Africa: Molecular Diagnostics Market for Other Hepatitis Diseases, by Country/Region, 2023-2030 (USD Million)
Table 208 Molecular Diagnostics Market for Respiratory Diseases, by Region, 2023-2030 (USD Million)
Table 209 Molecular Diagnostics Market for Respiratory Diseases, by Type, 2023-2030 (USD Million)
Table 210 North America: Molecular Diagnostics Market for Respiratory Diseases, by Country, 2023-2030 (USD Million)
Table 211 Europe: Molecular Diagnostics Market for Respiratory Diseases, By Country/Region, 2023-2030 (USD Million)
Table 212 Asia-Pacific: Molecular Diagnostics Market for Respiratory Diseases, by Country/Region, 2023-2030 (USD Million)
Table 213 Latin America: Molecular Diagnostics Market for Respiratory Diseases, by Country/Region, 2023-2030 (USD Million)
Table 214 Middle East & Africa: Molecular Diagnostics Market for Respiratory Diseases, by Country/Region, 2023-2030 (USD Million)
Table 215 Key Tuberculosis Molecular Diagnostic Products Available in Market
Table 216 Molecular Diagnostics Market for Tuberculosis, by Region, 2023-2030 (USD Million)
Table 217 North America: Molecular Diagnostics Market for Tuberculosis, By Country, 2023-2030 (USD Million)
Table 218 Europe: Molecular Diagnostics Market for Tuberculosis, By Country/Region, 2023-2030 (USD Million)
Table 219 Asia-Pacific: Molecular Diagnostics Market for Tuberculosis, By Country/Region, 2023-2030 (USD Million)
Table 220 Latin America: Molecular Diagnostics Market for Tuberculosis, by Country/Region, 2023-2030 (USD Million)
Table 221 Middle East & Africa: Molecular Diagnostics Market for Tuberculosis, by Country/Region, 2023-2030 (USD Million)
Table 222 Global Number of Newly Diagnosed Tuberculosis (Tb) Cases, 2023-2030 (Millions)
Table 223 Key Influenza Molecular Diagnostic Products Available in Market
Table 224 Molecular Diagnostics Market for Influenza, by Region, 2023-2030 (USD Million)
Table 225 North America: Molecular Diagnostics Market for Influenza, By Country, 2023-2030 (USD Million)
Table 226 Europe: Molecular Diagnostics Market for Influenza, By Country/Region, 2023-2030 (USD Million)
Table 227 Asia-Pacific: Molecular Diagnostics Market for Influenza, By Country/Region, 2023-2030 (USD Million)
Table 228 Latin America: Molecular Diagnostics Market for Influenza, By Country/Region, 2023-2030 (USD Million)
Table 229 Middle East & Africa: Molecular Diagnostics Market for Influenza, By Country/Region, 2023-2030 (USD Million)
Table 230 Key Pharyngitis Molecular Diagnostic Products Available in Market
Table 231 Molecular Diagnostics Market for Pharyngitis, by Region, 2023-2030 (USD Million)
Table 232 North America: Molecular Diagnostics Market for Pharyngitis, By Country, 2023-2030 (USD Million)
Table 233 Europe: Molecular Diagnostics Market for Pharyngitis, by Country/Region, 2023-2030 (USD Million)
Table 234 Asia-Pacific: Molecular Diagnostics Market for Pharyngitis, By Country/Region, 2023-2030 (USD Million)
Table 235 Latin America: Molecular Diagnostics Market for Pharyngitis, By Country/Region, 2023-2030 (USD Million)
Table 236 Middle East & Africa: Molecular Diagnostics Market for Pharyngitis, by Country/Region, 2023-2030 (USD Million)
Table 237 Other Respiratory Infectious Disease Diagnostic Products Available in Market
Table 238 Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Region, 2023-2030 (USD Million)
Table 239 North America: Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Country, 2023-2030 (USD Million)
Table 240 Europe: Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 241 Asia-Pacific: Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 242 Latin America: Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 243 Middle East & Africa: Molecular Diagnostics Market for Other Respiratory Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 244 Key Hospital-Acquired Infection-Based Molecular Diagnostic Products Available in Market
Table 245 Molecular Diagnostics Market for Hospital-Acquired Infections, By Region, 2023-2030 (USD Million)
Table 246 North America: Molecular Diagnostics Market for Hospital-Acquired Infections, by Country, 2023-2030 (USD Million)
Table 247 Europe: Molecular Diagnostics Market for Hospital-Acquired Infections, by Country/Region, 2023-2030 (USD Million)
Table 248 Asia-Pacific: Molecular Diagnostics Market Hospital-Acquired Infections, by Country/Region, 2023-2030 (USD Million)
Table 249 Latin America: Molecular Diagnostics Market for Hospital-Acquired Infections, by Country/Region, 2023-2030 (USD Million)
Table 250 Middle East & Africa: Molecular Diagnostics Market for Hospital-Acquired Infections, by Country/Region, 2023-2030 (USD Million)
Table 251 Key Vector-Borne Diseases Diagnostic Products Available in Market
Table 252 Molecular Diagnostics Market for Vector-Borne Diseases, by Region, 2023-2030 (USD Million)
Table 253 North America: Molecular Diagnostics Market for Vector-Borne Diseases, by Country, 2023-2030 (USD Million)
Table 254 Europe: Molecular Diagnostics Market for Vector-Borne Diseases, By Country/Region, 2023-2030 (USD Million)
Table 255 Asia-Pacific: Molecular Diagnostics Market Vector-Borne Diseases, By Country/Region, 2023-2030 (USD Million)
Table 256 Latin America: Molecular Diagnostics Market for Vector-Borne Diseases, by Country/Region, 2023-2030 (USD Million)
Table 257 Middle East & Africa: Molecular Diagnostics Market for Vector-Borne Diseases, by Country/Region, 2023-2030 (USD Million)
Table 258 Global Cases of Active Syphilis in Age Group from 15 to 49 Years, 2016-2022 (Thousands)
Table 259 Other Infectious Disease Molecular Diagnostic Products Available in Market
Table 260 Molecular Diagnostics Market for Other Infectious Diseases, By Region, 2023-2030 (USD Million)
Table 261 North America: Molecular Diagnostics Market for Other Infectious Diseases, by Country, 2023-2030 (USD Million)
Table 262 Europe: Molecular Diagnostics Market for Other Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 263 Asia-Pacific: Molecular Diagnostics Market for Other Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 264 Latin America: Molecular Diagnostics Market for Other Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 265 Middle East & Africa: Molecular Diagnostics Market for Other Infectious Diseases, by Country/Region, 2023-2030 (USD Million)
Table 266 Key Oncology Testing Products Available in Market
Table 267 Molecular Diagnostics Market for Oncology Testing, by Region, 2023-2030 (USD Million)
Table 268 Molecular Diagnostics Market for Oncology Testing, by Type, 2023-2030 (USD Million)
Table 269 North America: Molecular Diagnostics Market for Oncology Testing, by Country, 2023-2030 (USD Million)
Table 270 Europe: Molecular Diagnostics Market for Oncology Testing, By Country/Region, 2023-2030 (USD Million)
Table 271 Asia-Pacific: Molecular Diagnostics Market for Oncology Testing, By Country/Region, 2023-2030 (USD Million)
Table 272 Latin America: Molecular Diagnostics Market for Oncology Testing, by Country/Region, 2023-2030 (USD Million)
Table 273 Middle East & Africa: Molecular Diagnostics Market for Oncology Testing, by Country/Region, 2023-2030 (USD Million)
Table 274 Breast Cancer Incidence, by Region, 2022 Vs. 2030
Table 275 Molecular Diagnostics Market for Breast Cancer, by Region, 2023-2030 (USD Million)
Table 276 North America: Molecular Diagnostics Market for Breast Cancer, By Country, 2023-2030 (USD Million)
Table 277 Europe: Molecular Diagnostics Market for Breast Cancer, By Country/Region, 2023-2030 (USD Million)
Table 278 Asia-Pacific: Molecular Diagnostics Market for Breast Cancer, By Country/Region, 2023-2030 (USD Million)
Table 279 Latin America: Molecular Diagnostics Market for Breast Cancer, by Country/Region, 2023-2030 (USD Million)
Table 280 Middle East & Africa: Molecular Diagnostics Market for Breast Cancer, by Country/Region, 2023-2030 (USD Million)
Table 281 Colorectal Cancer Incidence, by Region, 2022 Vs. 2030
Table 282 Molecular Diagnostics Market for Colorectal Cancer, by Region, 2023-2030 (USD Million)
Table 283 North America: Molecular Diagnostics Market for Colorectal Cancer, by Country, 2023-2030 (USD Million)
Table 284 Europe: Molecular Diagnostics Market for Colorectal Cancer, By Country/Region, 2023-2030 (USD Million)
Table 285 Asia-Pacific: Molecular Diagnostics Market for Colorectal Cancer, By Country/Region, 2023-2030 (USD Million)
Table 286 Latin America: Molecular Diagnostics Market for Colorectal Cancer, by Country/Region, 2023-2030 (USD Million)
Table 287 Middle East & Africa: Molecular Diagnostics Market for Colorectal Cancer, by Country/Region, 2023-2030 (USD Million)
Table 288 Lung Cancer Incidence, by Region, 2022 Vs. 2030
Table 289 Molecular Diagnostics Market for Lung Cancer, by Region, 2023-2030 (USD Million)
Table 290 North America: Molecular Diagnostics Market for Lung Cancer, By Country, 2023-2030 (USD Million)
Table 291 Europe: Molecular Diagnostics Market for Lung Cancer, By Country/Region, 2023-2030 (USD Million)
Table 292 Asia-Pacific: Molecular Diagnostics Market for Lung Cancer, By Country/Region, 2023-2030 (USD Million)
Table 293 Latin America: Molecular Diagnostics Market for Lung Cancer, By Country/Region, 2023-2030 (USD Million)
List of Figures
Figure 1 Research Design Methodology
Figure 2 Key Primary Sources
Figure 3 Breakdown of Primary Interviews: Supply-Side and Demand-Side Participants
Figure 4 Breakdown of Primary Interviews: by Company Type, Designation, And Region
Figure 5 Bottom-Up Approach: Company Revenue Estimation Approach
Figure 6 Cagr Projections: Supply-Side Analysis
Figure 7 Molecular Diagnostics Market: Top-Down Approach
Figure 8 Data Triangulation Methodology
Figure 9 Molecular Diagnostics Market: Research Assumptions
Figure 10 Molecular Diagnostics Market, by Product & Service, 2025 Vs. 2030 (USD Million)
Figure 11 Molecular Diagnostics Market, by Test Type, 2025 Vs. 2030 (USD Million)
Figure 12 Molecular Diagnostics Market, by Sample Type, 2025 Vs. 2030 (USD Million)
Figure 13 Molecular Diagnostics Market, by Technology, 2025 Vs. 2030 (USD Million)
Figure 14 Molecular Diagnostics Market, by Application, 2025 Vs. 2030 (USD Million)
Figure 15 Molecular Diagnostics Market, by Technique, 2025 Vs. 2030 (USD Million)
Figure 16 Molecular Diagnostics Market, by Clinical Application, 2025 Vs. 2030 (USD Million)
Figure 17 Molecular Diagnostics Market, by End-user, 2025 Vs. 2030 (USD Million)
Figure 18 Molecular Diagnostics Market, by Region, 2025 Vs. 2030 (USD Million)
Figure 19 Increasing Prevalence of Infectious Diseases and Cancer to Drive Market
Figure 20 Reagents & Kits Segment to Dominate Market During Forecast Period
Figure 21 Lab Tests Segment to Lead Market During Forecast Period
Figure 22 Blood, Serum, and Plasma Segment to Account for Largest Share During Forecast Period
Figure 23 Polymerase Chain Reaction Segment to Achieve Largest Share During Forecast Period
Figure 24 Infectious Disease Diagnostics Segment to Account for Largest Share During Forecast Period
Figure 25 Multiplex Testing Segment to Account for Significant Share During Forecast Period
Figure 26 Diagnostic Segment to Dominate Market During Forecast Period
Figure 27 Diagnostic Laboratories Segment to Lead Market in 2030
Figure 28 North America to Account for Largest Share During Forecast Period
Figure 29 Molecular Diagnostics Market: Drivers, Restraints, Opportunities, And Challenges
Figure 30 Incidence of Hiv, by Region, 2024
Figure 31 Patent Analysis for Isothermal Nucleic Acid Amplification Technologies, January 2015-December 2024
Figure 32 Molecular Diagnostics Market: Value Chain Analysis
Figure 33 Molecular Diagnostics Market: Supply Chain Analysis
Figure 34 Molecular Diagnostics Market: Ecosystem Analysis
Figure 35 Molecular Diagnostics Market: Porter’S Five Forces Analysis
Figure 36 Molecular Diagnostics Market: Trends and Disruptions Impacting Customer Business
Figure 37 Influence of Stakeholders on Buying Process, by Product & Service
Figure 38 Key Buying Criteria, by Product & Service
Figure 39 Number of Deals & Total Funding, 2021-2025
Figure 40 Molecular Diagnostics Market: Key Use Cases
Figure 41 North America: Molecular Diagnostics Market Snapshot
Figure 42 Asia-Pacific: Molecular Diagnostics Market Snapshot
Figure 43 Revenue Analysis of Key Players, 2022-2024 (USD Million)
Figure 44 Market Share Analysis of Key Players, 2024
Figure 45 Molecular Diagnostics Market: Company Evaluation Matrix (Key Players), 2024
Figure 46 Molecular Diagnostics Market: Company Footprint
Figure 47 Molecular Diagnostics Market: Company Evaluation Matrix (Startups/Smes), 2024
Figure 48 Ev/Ebitda of Key Vendors
Figure 49 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 50 Brand/Product Comparison for Molecular Diagnostic Instruments
Figure 51 Danaher Corporation: Company Snapshot (2024)
Figure 52 F. Hoffmann-La Roche Ltd.: Company Snapshot (2024)
Figure 53 Illumina, Inc.: Company Snapshot (2024)
Figure 54 Hologic, Inc.: Company Snapshot (2024)
Figure 55 Biomérieux: Company Snapshot (2024)
Figure 56 Abbott Laboratories: Company Snapshot (2024)
Figure 57 Thermo Fisher Scientific Inc.: Company Snapshot (2024)
Figure 58 Qiagen N.V.: Company Snapshot (2024)
Figure 59 Revvity, Inc.: Company Snapshot (2024)
Figure 60 Myriad Genetics, Inc.: Company Snapshot (2024)
Figure 61 Siemens Healthineers Ag: Company Snapshot (2024)

Companies Mentioned

  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Hologic, Inc.
  • Biomérieux
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Qiagen N.V.
  • Revvity, Inc.
  • Myriad Genetics, Inc.
  • Siemens Healthineers Ag
  • Becton, Dickinson and Company (Bd)
  • Grifols, S.A.
  • Quidelortho Corporation
  • Diasorin S.P.A.
  • Exact Sciences Corporation
  • Genetic Signatures
  • Agilent Technologies, Inc.
  • Mdxhealth
  • Biocartis
  • Medigen Biotechnology Corp.
  • Vela Diagnostics
  • Amoy Diagnostics Co. Ltd.
  • Bruker Corporation (Elitechgroup)
  • Molbio Diagnostics Limited
  • Geneombiotechnologies
  • Savyon Diagnostics
  • Uniogen Oy

Table Information